ClinicalTrials.gg
Not yet recruitingNCT07292896Updated Dec 18, 2025

A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography

An observational study in Healthy Adults, Pulmonary Hypertension and Tricuspid Regurgitation, sponsored by First Hospital of China Medical University. Not yet recruiting at 25 sites in China. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by First Hospital of China Medical University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,640
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Hypertension, Pulmonary with a site in China — 31 open to participants now, 36 under way, 5 of them phase 3. Hypertension, Pulmonary · China.

Planned enrollment
9th of 36
2,640 · median 750
Started
2025
with 9 others
Observational
36 of 85
18 open now
Primary completion
2026-12
later than 17 of 35 live
Registered
79th of 85
by date

Among the 85 studies in Hypertension, Pulmonary with a site in China, this one is the 9th largest by planned enrollment of the 36 observational ones that give a count, is one of 10 that started in 2025, is one of 36 observational ones, reaches primary completion later than 17 of the 35 other live ones, and was the 79th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

31 of the 85 studies in Hypertension, Pulmonary with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Hypertension, Pulmonary with a site in China, or all of them as a file.
02

Study summary

This multicenter study aims to establish the normal reference range of the Right Atrioventricular Coupling Index (RACI) in healthy Chinese adults using AI-based 3DE technology. It will also analyze the correlation between RACI and physiological parameters such as age, gender, and body surface area. Additionally, the study will explore the variation characteristics of RACI in patients with pulmonary hypertension, heart failure, tricuspid regurgitation, and atrial septal defect, and evaluate the clinical value of RACI in disease diagnosis, differential diagnosis, and risk stratification.

03

Conditions studied

  • Healthy Adults
  • Pulmonary Hypertension
  • Tricuspid Regurgitation
  • Heart Failure
  • Atrial Septal Defect

Keywords

  • Right Atrioventricular Coupling Index
  • 3D Echocardiography
  • AI-assisted Imaging
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This study enrolls 5 groups (18-79 years) from clinics/community:

Healthy Adults: Han Chinese with normal cardiovascular function (vitals, labs, ECG, echo; no structural heart disease/systemic diseases/poor ultrasound).

Pulmonary Hypertension: Diagnosed via right heart catheter (mPAP ≥20 mmHg, 2022 ESC/ERS); excluded if with left heart disease, interfering conditions, organ dysfunction, malignancy, or prior pulmonary surgery.

Heart Failure: Meets 2022 AHA/ACC/HFSA criteria; excluded if with significant valvular disease.

Tricuspid Regurgitation: Echo-confirmed moderate/severe regurgitation; excluded if with interfering pericardial/arrhythmic issues or congenital heart disease/residual lesions.

Atrial Septal Defect: Echo/TEE-confirmed secundum defect (untreated or stable ≥3mo post-op); excluded if with complex congenital heart disease.

All undergo standardized clinical/echo assessments for cardiac structure/function.

Eligibility criteria

Healthy Adults Group

Inclusion Criteria:

  • Participants must meet all of the following criteria to be enrolled:

    1. Of Han Chinese ethnicity
    2. Aged 18-79 years
    3. Normal blood pressure (\< 140/90 mmHg)
    4. Normal fasting blood glucose
    5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)
    6. Normal complete blood count results ( concentration, white blood cell count, red blood cell count, count)
    7. Normal liver and renal function ( \< 2× ; normal creatinine and blood urea nitrogen)
    8. Normal results (occasional atrial premature beats may be enrolled at the investigator's discretion)
    9. No structural heart disease and normal cardiac function confirmed by echocardiography

Exclusion Criteria:

Participants will be excluded if they meet any of the following criteria:

  1. cardiac valve regurgitation (≥ mild severity)
  2. Respiratory diseases: acute or chronic respiratory disorders
  3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.
  4. Abnormal liver function (alanine transaminase > 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)
  5. Other systemic diseases: anemia, , connective tissue disease, large artery/peripheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.
  6. Pregnant or lactating women
  7. Professional athletes
  8. Poor-quality ultrasound images that cannot support parameter measurement and analysis

Pulmonary Hypertension Group

Inclusion Criteria:

Patients must meet all of the following criteria to be enrolled:

  1. Aged 18-79 years
  2. Confirmed diagnosis via right heart catheterization: mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, in accordance with the 2022 ESC/ERS guidelines

Exclusion Criteria:

Patients will be excluded if they meet any of the following criteria:

  1. Unable to complete right heart catheterization or pressure-volume loop assessment
  2. Complicated with significant left heart disease ( [LVEF] \< 50%, significant mitral valve disease)
  3. Pericardial disease or arrhythmias (e.g., atrial fibrillation) that severely impair right heart function evaluation
  4. Poor-quality images that prevent accurate measurement of right atrial or right ventricular parameters
  5. Concurrent liver or renal disease
  6. Concurrent malignancy
  7. History of surgical procedures such as pulmonary endarterectomy or balloon pulmonary angioplasty

Heart Failure Group

Inclusion Criteria:

Patients must meet all of the following criteria to be enrolled:

  1. Aged 18-79 years
  2. Meets the 2022 AHA/ACC/HFSA diagnostic criteria for heart failure

Exclusion Criteria:

Patients will be excluded if they meet any of the following criteria:

1.Complicated with significant valvular heart disease (e.g., severe mitral regurgitation, severe tricuspid regurgitation, etc.)

Tricuspid Regurgitation Group

Inclusion Criteria:

Patients must meet all of the following criteria to be enrolled:

  1. Moderate or severe primary or secondary tricuspid regurgitation confirmed by echocardiography
  2. Aged 18-79 years

Exclusion Criteria:

Patients will be excluded if they meet any of the following criteria:

  1. Pericardial disease or arrhythmias (persistent atrial fibrillation) that interfere with measurements
  2. Congenital heart disease or residual lesions after surgical correction

Atrial Septal Defect Group

Inclusion Criteria:

Patients must meet all of the following criteria to be enrolled:

  1. Secundum atrial septal defect confirmed by echocardiography or transesophageal echocardiography
  2. Patients who have not undergone closure or surgical correction, or stable patients with > 3 months postoperatively
  3. Aged 18-79 years

Exclusion Criteria:

1.Complicated with other complex congenital heart diseases.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,640 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Adults Group

    Healthy adults aged 18 to 79 years are planned to be stratified into 6 age groups: 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and ≥70 years. Each age group will include 120 participants of each sex.

  • Pulmonary Hypertension Group

    This group comprises adults with a confirmed diagnosis of mean pulmonary artery pressure (mPAP) ≥20 mmHg via right heart catheterization, in accordance with the diagnostic criteria for pulmonary hypertension specified in the 2022 ESC/ERS Guidelines.

  • Tricuspid Regurgitation Group

    Adults with moderate or severe primary/secondary tricuspid regurgitation confirmed by echocardiography.

  • Atrial Septal Defect Group

    Adults with atrial septal defect confirmed by echocardiography or transesophageal echocardiography, including non-intervened patients, those who underwent closure/surgical correction, and stable patients \> 3 months after surgery.

  • Heart Failure Group

    Adults meeting the 2022 AHA/ACC/HFSA diagnostic criteria for heart failure are classified into three subgroups based on left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF, LVEF \< 40%), heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 40-49%), and heart failure with preserved ejection fraction (HFpEF, LVEF ≥ 50%).

06

What researchers measure

Primary outcomes

  1. Right Atrioventricular Coupling Index (RACI)

    RACI links the volumes of the right atrium (RA) and right ventricle (RV), with the degree of their volume matching reflecting their synergistic functional status during hemodynamic regulation

    Time frame: At study enrollment (baseline)

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 12 months is below that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2025
First posted
Dec 18, 2025
StartEst.
Dec 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07292896
Lead sponsor
First Hospital of China Medical University
Responsible party
Chunyan Ma (Chief of Cardiovascular Ultrasound, First Hospital of China Medical University) — Principal investigator
First posted
Dec 18, 2025
Start date
Dec 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 18, 2025

Study contacts

Chunyan Ma, MD
Contact
mcy_echo@163.com
+86 13998816448
Chunyan Ma, MD
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion